Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MYOC | Q99972 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069292 | 0.86 | MAPT (0.50) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL30825949 | 0.86 | MAPT (0.50) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL3559340 | 0.85 | MAPT (0.50) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL31665956 | 0.85 | MAPT (0.50) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL3566164 | 0.85 | KMT2A (0.52) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL13527385 | 0.85 | KMT2A (0.52) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL3573967 | 0.83 | MAPT (0.66) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL30995559 | 0.82 | MAPT (0.47) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL590790 | 0.82 | MAPT (0.47) | MAPTGAAKMT2AMEN1POLB | |
| SCHEMBL896599 | 0.81 | ALDH1A1 (0.56) | MAPTGAAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666873-B2 | N-phenyl-(2R,5S)dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | ASTELLAS PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7297698-B2 | N-phenyl-(2R,5S) dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-20 | — | — | US | disclosed |
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1557411-A1 | N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | BPHL, QDPR, SRD5A2 | MAPT 4453/4885GAA 4595/4885KMT2A 691/4885 |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | BPHL, AR, SRD5A2 | MAPT 4272/4885GAA 4303/4885KMT2A 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.